Loading
Proved PSMA PET is far more accurate than conventional scans for staging, with less radiation.
proPSMA, registered as ANZCTR12617000005358, sponsored by Peter MacCallum Cancer Centre and ANZUP and reported in the Lancet in 2020, proved that PSMA PET/CT is far more accurate than CT plus bone scan for staging high-risk localised prostate cancer, with less radiation. It randomised 302 men, found an accuracy of 92 percent for PSMA PET against 65 percent for conventional imaging, produced fewer equivocal findings and changed management more often. OnCo links it to PSMA PET, Peter MacCallum, ANZUP, Michael Hofman, Ian Davis and Declan G. Murphy, and its findings are consistent with the OSPREY and CONDOR studies for the fluorine-18 tracer DCFPyL. Whether better staging translates into better outcomes, rather than only different decisions, is the open question that follows any diagnostic accuracy trial. PSMA PET has its own page.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
302 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Accuracy for pelvic nodal or distant metastases (AUC)primary | PSMA PET/CT | 150 | 92% | - | <0.0001 | link |
| CT + bone scan | 152 | 65% |
Shares Michael Hofman, ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA PET.
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, Prostate cancer.
Shares Michael Hofman, ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA PET.
Shares ORIOLE, PSMA PET, Prostate cancer.
Shares ANZUP Cancer Trials Group, Prostate cancer.
Shares Michael Hofman, Peter MacCallum Cancer Centre, PSMA PET.
Shares ANZUP Cancer Trials Group, Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.